Yun Sun Choe, MD
Rheumatology · Tacoma, WANPI 1093866170
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Amgen at 25.9% of the total.
Across 70 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$302
- E.r. Squibb & Sons, L.L.C.$132
- AbbVie$126
- Johnson & Johnson$122
- Pfizer$116
- Novartis$77
- plus $290 from 8 others
Across 2 payments — averaging $2074.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$4K
- E.r. Squibb & Sons, L.L.C.$30
What the payments were for
- Food & beverage$1,164100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 21 | $302 |
| E.r. Squibb & Sons, L.L.C. | 7 | $132 |
| AbbVie | 6 | $126 |
| Johnson & Johnson | 6 | $122 |
| Pfizer | 9 | $116 |
| Novartis | 4 | $77 |
| Lilly USA, LLC | 4 | $74 |
| Mallinckrodt Enterprises LLC | 3 | $59 |
| Hikma Pharmaceuticals USA | 2 | $35 |
| Genentech USA, Inc. | 2 | $32 |
| GSK | 2 | $29 |
| Merck | 2 | $26 |
| UCB, Inc. | 1 | $19 |
| Pacira Therapeutics, Inc. | 1 | $16 |
How this compares
$1,164 in reported general payments places this provider in the 65th percentile of 157 rheumatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 19 | $87,730 |
| Amjevita(Cf) AutoinjectorAdalimumab-Atto | 28 | $22,360 |
| RasuvoMethotrexate/Pf | 16 | $8,933 |
| MethotrexateMethotrexate Sodium | 152 | $2,554 |
| Hydroxychloroquine Sulfate | 76 | $2,363 |
| Prednisone | 206 | $2,000 |
| Leflunomide | 40 | $871 |
| Colchicine | 33 | $855 |
| Febuxostat | 11 | $361 |
| Cefdinir | 15 | $330 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $294 |
| Allopurinol | 28 | $275 |
| Meloxicam | 25 | $193 |
| Alendronate Sodium | 13 | $102 |
| Oxycodone Hcl | 13 | $89 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Tacoma
- Robert EttlingerTacoma$232K
- Brittany AhmedTacoma$4K
- Patricia PapadopoulosTacoma$2K
- Daniel Ene-StroescuTacoma$1K
- Ofelya GevorgyanTacoma$909
- Stanford PengSeattle$3.5M
- Jeff PetersonBothell$2.3M
- Philip MeaseSeattle$2.1M
- Richard JimenezBothell$155K
- Howard KenneySpokane$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.